Friday, June 22, 2018

The Foundational Role of Physiologic, Long‐Acting Basal Insulin—Optimizing the Safety‐Efficacy Equation in Vulnerable Patients with T2D

Professor Vivian A. Fonseca, MD – Program Co-Chair

Tullis Tulane Alumni Chair in Diabetes

Juan P. Frias, MD, FACE – Program Co-Chair

University of California, San Diego, California

Pablo F Mora, MD, FACE, CDE

University of Texas Southwestern Medical Center at Dallas

Lawrence Blonde, MD, FACP, MACE

Ochsner Medical Center

Friday, June 22, 2018

The Mechanistic and Therapeutic Rationale for Dual SGLT1/2 Inhibition in Adults with Type 1  Diabetes

John B. Buse, MD, PhD – Program Co-Chair

University of North Carolina School of Medicine

Robert Henry, MD – Program Co-Chair

University of California‚ San Diego

Satish K. Garg, MD

University of Colorado School of Medicine

Melanie J. Davies, CBE, MB, ChB, MD, FRCP, FRCGP

University of Leicester School of Medicine

 

Saturday June 23, 2018

Multi-Mechanistic, Insulin-Based Approaches for Achieving HA1c/PPG Targets and Optimizing Safety in Challenging Patients with T2D

Professor Vivian A. Fonseca, MD – Program Co-Chair

Tulane University Health Sciences Center

Juan P. Frias, MD, FACE – Program Co-Chair

University of California, San Diego, California

Pablo F Mora, MD, FACE, CDE

University of Texas Southwestern Medical Center at Dallas

Lawrence Blonde, MD, FACP, MACE

Ochsner Medical Center

Saturday, June 23, 2018

The Landmark Evidence and Clinical Rationale for PCSK9 Inhibition in the Diabetic Patient

Professor Deepak L. Bhatt, MD – Program Chair

Harvard Medical School

James M. McKenney, PharmD

Virginia Commonwealth University

Lawrence A. Leiter, MD

University of Toronto

Jennifer Robinson, MD

University of Iowa School of Medicine

 

Basal Insulin in Vulnerable Patients
with Type 2 Diabetes

Complementary Insulin Combinations
to Optimize Glycemic Control in T2D

Blindness Prevention in Patients
with DME and AMD

Optimizing Glycemic Control with Basal Insulin
in Complex Patients with Diabetes

Optimizing Management of the 
Diabetic Heart

Complementary Basal Insulin Plus Incretin
System-Targeted Agents in Challenging
Patients with Diabetes

CV Risk Reduction and Glycemic
Control in T2D